An initiative of Flandersbio

Listed companies

Listed companies

in english

The combined market cap of Belgian SME biotech companies gained top position in the European ranking. The fact that the number of qualifying companies is 2 to 3 times smaller than in other European countries confirms the intrinsic quality of the Belgian public biotech sector.

argenx

arGEN-X creates novel, antibody-based medicines using the SIMPLE Antibody™ platform to generate leads of unparalleled functional diversity, allowing optimal selection of mAb candidates. The proprietary NHance™ half-life extension technology also allows tailoring of antibodies for attractive dosing regimes, patient convenience and pharmacoeconomics. arGEN-X has demonstrated its ability to provide first and best in class biopharmaceuticals in internal and partnered therapeutic antibody programs.

argenx on FlandersBio.be

 

Chart IPO Statistics Pipeline Contact

Click on the chart to follow the daily exchange rate.

View the NYSE Euronext chart

  • Listing date: :   10/07/2014

View chart De Tijd

Product Indications and progress Partner
ARGX-109 Auto-immunity and cancer RuiYi
 
ARGX-110 Heme malignancies
 
ARGX-110 Solid tumors
 
ARGX-111 Solid tumors and Heme malignancies
 
ARGX-112 Atopic dermatitis
 
ARGX-113 Auto-immunity
 
- Undisclosed Shire
 
- Undisclosed Bayer
 
- Undisclosed Boehringer Ingelheim
 

Investor Relations:
Joke Comijn, Corporate Communication Manager
Email:
Phone: +32 9 241 58 41

Address details:
Industriepark Zwijnaarde 7, Building C, 9052 Ghent, Belgium
Website: http://www.argen-x.com
Email:

Back to top

Print